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β-Thalassemia is one of the most common inherited anemias, with no effective cure for most
patients. The pathophysiology reﬂects an imbalance between α- and β-globin chains with an
excess of free α-globin chains causing ineffective erythropoiesis and hemolysis. When
α-thalassemia is co-inherited with β-thalassemia, excess free α-globin chains are reduced
signiﬁcantly ameliorating the clinical severity. Here we demonstrate the use of CRISPR/Cas9
genome editing of primary human hematopoietic stem/progenitor (CD34+) cells to emulate
a natural mutation, which deletes the MCS-R2 α-globin enhancer and causes α-thalassemia.
When edited CD34+ cells are differentiated into erythroid cells, we observe the expected
reduction in α-globin expression and a correction of the pathologic globin chain imbalance in
cells from patients with β-thalassemia. Xenograft assays show that a proportion of the edited
CD34+ cells are long-term repopulating hematopoietic stem cells, demonstrating the
potential of this approach for translation into a therapy for β-thalassemia.
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Thalassemia is a disorder of hemoglobin synthesischaracterized by severe anemia, which requires intensivesupportive treatment from early childhood1. The most
common and severe form of this disease (β-thalassemia) results
from an absent or reduced production of normal β-globin chains2.
Most aspects of the pathophysiology of β-thalassemia can be
explained by the presence of excess α-globin chains, which can no
longer pair with the reduced numbers of β-globin chains, found in
patients with β-thalassemia, to produce normal hemoglobin tet-
ramers (α2β2). Excess α-globin chains precipitate both in red cell
precursors (causing ineffective erythropoiesis) and mature red
cells (causing hemolysis). Clinical and genetic data have clearly
shown that when α-thalassemia is co-inherited with β-thalassemia,
there is reduced expression of the α-globin genes, less globin chain
imbalance, and reduced numbers of free α-globin chains, sig-
niﬁcantly ameliorating the clinical severity of β-thalassemia3. By
contrast, inheritance of a higher than normal number of α-globin
genes (5 or 6 rather than 4) substantially worsens the disease
phenotype, emphasizing that excess α-globin chains are the major
determinant of the clinical severity of β-thalassemia4, 5.
The human α-globin gene locus is situated in the short arm of
chromosome 16 with two copies of the α-globin gene on
each chromosome (αα/αα). Expression of the α-globin genes is
controlled by four enhancers (MCS-R1 to R4) located 10–50 kb
upstream of the genes6, 7. Previous studies, including transgenic
experiments combined with observations of naturally occurring
mutations, have shown that a multi-species conserved sequence,
which lies 40 kb upstream of the α-globin locus (MCS-R2, also
known as HS-40), is the most powerful enhancer of α-globin gene
expression8–10. We have previously characterized MCS-R2 in
detail and shown that its activity is contained within a ~260 bp
core fragment, including several well-conserved erythroid
transcription factor binding sites11. A 1.1 kb deletion removing
MCS-R2 in a humanized mouse model has been shown to result
in a signiﬁcant reduction of human α-globin expression9. More
recently, Coelho et al.12 reported a patient homozygous for a rare
3.3 kb deletion, which uniquely removes MCS-R2 and results in a
signiﬁcant downregulation of α-globin gene expression. Thus we
hypothesized that if a targeted mutation of MCS-R2 was to be
created it should result in a reduction of α-globin expression to
levels beneﬁcial to patients with β-thalassemia.
Genome editing using the CRISPR/Cas9 (clustered, regularly
interspaced, short palindromic repeat/CRISPR-associated protein
9) system provides a realistic approach to the treatment of human
genetic diseases including hemoglobinopathies13. These nucleases
create double-strand breaks at speciﬁc, chosen locations in the
genome and, when repaired, create mutations at the targeted
sites14. Although CRISPR/Cas9 can be used to promote either
homology-directed recombination (HDR) or non-homologous
end joining, hematopoietic stem cells (HSC) are currently largely
limited to the latter form of editing since, despite some recent
developments15, HDR remains an inefﬁcient process in HSCs16.
This means that deleting and inactivating an enhancer is
currently a much more tractable approach to ameliorating
β-thalassemia than directly repairing the β-globin gene or
removing the α-globin genes by HDR.
Here we show the use of CRISPR/Cas9 genome editing tech-
nology to create a targeted mutation of the MCS-R2 core element
in human HSCs to mimic the effects of natural mutations,
which knockdown α-globin expression. We demonstrate
successful knockdown of α-globin expression in vitro in erythroid
cells generated by genome-edited HSCs to levels beneﬁcial in
β-thalassemia without perturbing erythroid differentiation or
having detectable off-target events. Finally, we show that
this form of engineering occurs in long-term repopulating HSC
(LT-HSC), the cell population currently used in clinical practice
for HSC therapy in blood diseases, demonstrating the potential of
this approach for translation into a therapy for β-thalassemia.
Results
A natural deletion that uniquely removes MCS-R2 enhancer.
A previously reported patient (MC) is homozygous for a very
rare 3.3 kb deletion (called (αα)ALT), which uniquely removes
MCS-R2 but leaves the α-globin genes and all other enhancer
elements intact12. MC is a member of a pedigree (Fig. 1a) that
originates from Portugal and was evaluated in greater detail
(Supplementary Table 1). Hematological analysis conﬁrmed
that MC has hypochromic microcytic anemia (Figs. 1b, c); 51% of
his peripheral blood red blood cells (RBC) were positive for
hemoglobin H (HbH) inclusion bodies conﬁrming a diagnosis
of α-thalassemia leading to HbH disease (Fig. 1d). α-Globin
messenger RNA (mRNA) levels of MC’s peripheral blood are
reduced and multiplex ligation-dependent probe ampliﬁcation
analysis12 conﬁrmed the absence of MCS-R2 in its natural geno-
mic location, but did not exclude the possibility of its presence in
an ectopic locus. To examine this we performed Southern blot
analysis using a probe speciﬁc to MCS-R2, which conﬁrmed the
absence of the MCS-R2 region anywhere in the genome (Fig. 1e).
Interestingly, in the (αα)ALT mutation, the 3.3 kb deletion is
associated with the insertion of a 39 nucleotide orphan segment,
whose sequence was not found anywhere in the human genome.
Our search for canonical binding motifs for both general
transcription factors, and erythroid-speciﬁc factors within this
orphan sequence did not reveal motifs with any known regulatory
potential. Next, we examined the presence of histone 4 acetylation
(H4Ac) or binding of the stem cell leukemia (SCL) complex,
which are signatures of active chromatin within this orphan insert
sequence. Chromatin immunoprecipitation (ChIP-qPCR) across
this sequence conﬁrmed the absence of enrichment for these
activating chromatin marks (Figs. 1f, g).
To assess whether the function of MCS-R2 was assumed by any
other region within or beyond the α-globin cluster, we undertook
ChIP-Seq (using an anti-pan-H4 acetylation antibody) to give the
greatest likelihood of detecting any newly activated chromatin
(Fig. 1h). No new putative regulatory elements were detected,
with the only additional ﬁnding of note being the loss of a single
H4Ac peak at the HBM promoter. This corresponds to a short
deletion in the region of the HBM promoter, conﬁrmed by
Southern blot. This region does not contribute to normal α-globin
transcription17 and its loss is not associated with any expected
reduction in α-globin levels.
These data support experimental studies in the mouse18, which
deﬁne MCS-R2 as the major (but not the only) regulatory element
controlling expression of α-globin RNA. Its loss from the natural
chromosomal environment results in a signiﬁcant reduction of
α-globin transcription in cis. The clinical phenotypes of
thalassemia trait in the heterozygous patient RC and of HbH
disease in patient MC, who carries this deletion in homozygosity,
demonstrate that deletion of MCS-R2 causes a signiﬁcant
(>50%), but not total reduction in α-globin expression in both
homozygous and heterozygous states. However, of importance for
this study, the absence of MCS-R2 in the homozygous state did
not result in any other phenotypic abnormalities in MC,
demonstrating that its unique functional signiﬁcance is conﬁned
to expression of the α-globin locus.
Targeted in vitro deletion of MCS-R2 to knockdown α-globin.
Next, we hypothesized that creating a targeted deletion of
MCS-R2 would phenocopy the effects seen in MC and RC in
homozygous and heterozygous states, respectively. Thus the
removal of the ~260 bp core element of MCS-R2 in human
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erythroid cells should result in a reduction in α-globin expression
to levels previously shown to be beneﬁcial in patients with
β-thalassemia. To do this, we designed several short guide RNAs
(sgRNA) complementary to target sequences both up- and
downstream of the MCS-R2 core element (Fig. 2a; Supplementary
Table 2) to generate CRISPR plasmid pairs to use in combination
to create two double-strand breaks at either end of the enhancer.
When repaired this should introduce targeted deletions. These
sgRNAs were cloned into a plasmid vector (Addgene plasmid
48138: pSpCas9(BB)-2A-GFP (pX458)) that contains a gene
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encoding green ﬂuorescent protein (GFP) fused to a Cas9 gene.
We then co-transfected primary human CD34+ cells, obtained
from normal, non-thalassemia controls, with pairs of
CRISPR plasmids (Supplementary Fig. 1). The live-transfected
cell populations were sorted by GFP expression (Supplementary
Fig. 2; Fig. 2b) and screened for the predicted mutations. Through
this preliminary screening we identiﬁed four optimal CRISPR
plasmid pairs, which generated targeted deletions at the
highest frequencies (Supplementary Fig. 3). Deletion efﬁciency of
these CRISPR pairs was veriﬁed by two independent methods
and was consistently over 70% when using three out of four pairs
(Figs. 2c, d). The accuracy of editing was then determined
by Sanger sequencing (Fig. 2e). Next we differentiated these
transfected CD34+ cells along the erythroid lineage to evaluate
globin gene expression. As expected, and similar to the
observations made in MC, with all four CRISPR plasmid pairs,
deletions of MCS-R2 (ΔMCS-R2) resulted in selective reduction
in α-globin expression without altering the expression of the
β-globin gene (Fig. 2f).
Single-cell assays conﬁrm α-globin knockdown by ΔMCS-R2.
Next, to precisely dissect the effects of CRISPR/Cas9-mediated
ΔMCS-R2, we performed single-cell assays using Terasaki
multiwell plates, which were superior to the traditional
methylcellulose-based colony assays in minimizing cross-
contamination between clones. We transfected CD34+ cells
with a pair of CRISPR plasmids (Cr2 + Cr12) and then sorted
these cells using ﬂow cytometry to generate single cells in
individual wells. Following erythroid differentiation, individual
clones were assayed for genotype and globin gene expression,
which enabled us to determine the correlations between
the dosages of mutant alleles and globin gene expression, and
conﬁrm the editing efﬁciency. Genotype analysis of these
clones by PCR and sequencing revealed a variety of editing
outcomes not only limited to the expected mutations resulting
in a mixture of different genotypes, which included MCS-R2
non-deletions (wild type), heterozygous and homozygous
ΔMCS-R2 mutations, MCS-R2 inversions, and unpredicted
mutations (Figs. 3a, b; Supplementary Fig. 4). Analysis of globin
gene expression of individual erythroid clones demonstrated
signiﬁcant reductions in α/β-globin mRNA ratios in clones
with heterozygous (median 36% compared to normal) and
homozygous (median 3% compared to normal) ΔMCS-R2
mutations (Fig. 3c) thus conﬁrming the selective downregulation
of α-globin by deletion of MCS-R2. The α/β-globin mRNA ratios
in clones with inversions of the MCS-R2 were similar to those
without mutations (Fig. 3d). Similar results were observed in
single-cell clone analysis of CD34+ cells transfected with another
independent CRISPR pair (Cr1 + Cr8) thus corroborating the
results (Supplementary Figs. 5 and 6).
Genome-edited cells have no detectable off-target effects. To
explore any off-target effects of MCS-R2 deletion by CRISPR, we
identiﬁed potential genomic off-target loci for the four sgRNA
(Cr1, Cr2, Cr8, and Cr12) using the Sanger off-target prediction
tool (Supplementary Table 3). Sequencing of the DNA from
genome-edited clones did not identify any off-target activity at
these sites (Fig. 3e; Supplementary Fig. 5; Supplementary Table 4)
conﬁrming the speciﬁc on-target activity of the CRISPR plasmids
used here.
To examine the effect of deleting MCS-R2 on the differentia-
tion of CD34+ cells following genome editing, we cultured the
edited cells in conditions that favor the erythroid lineage.
Morphological analysis of stained cytospins and immunopheno-
typic characterization using erythroid-speciﬁc cell surface
markers were performed. CRISPR-edited cells demonstrated the
same patterns of differentiation as unedited control cells
(Supplementary Fig. 7).
Genome-edited HSCs retain long-term repopulating ability. If
genome editing of MCS-R2 is to become a realistic therapeutic
approach in β-thalassemia, targeted mutations must be produced
in LT-HSC. Human CD34+ cells are used in all current stem cell
transplantation protocols for blood diseases, but they are known
to be a heterogeneous collection of hematopoietic progenitors and
rare LT-HSCs (so called HSCs;<0.5% of total nucleated bone
marrow cells). To exclude the possibility that genome editing
occurred in progenitors but not LT-HSCs, CRISPR-transfected
CD34+ cells were injected into the bone marrows of four
sub-lethally irradiated female NSG mice (80,000 cells per mouse)
and their bone marrow was harvested after 12 weeks (Figs. 4a, b).
All four mice demonstrated long-term multi-lineage (lymphoid
and myeloid) engraftment (range 0.8–34% human leukocytes),
and three had particularly high levels (27–34% hCD45+) (Fig. 4c;
Supplementary Fig. 8). Human CD45+ cells obtained from the-
se bone marrows were sorted and DNA was screened for the
predicted edits from these three mice: two had genome-edited
cells of which one (xenograft #3) had an edited allele frequency of
71% (Fig. 4d). Although not found in the in vitro analyses, in
this analysis we found a slightly larger deletion (271 bp instead of
241 bp) presumably due to exonuclease cut back from the
CRISPR/Cas9 cut sites (Fig. 4e). Nevertheless, this deletion
removes the key transcription factor binding sites as in the
experimental plan. Flow cytometry analysis of harvested bone
marrow of xenograft #3 mice showed that 15.5% of all human
CD45+ cells were positive for human CD34+.
To determine if we had successfully edited LT-HSC, we
performed serial, secondary transplantation with hCD45+ cells
from the primary engrafted mice (100,000 cells per mouse, n= 3).
We detected multi-lineage engraftment of hCD45+ cells in 2/3
mice (range 29.7–36.9% human leukocytes). We also performed
Fig. 1 Characterization of a rare natural mutation ((αα)ALT) conﬁned to MCS-R2. a Kindred showing patient (MC) homozygous for the (αα)ALT mutation
and his heterozygote daughters. b Hemoglobin level and red cell parameters of MC and RC (who is heterozygous for the (αα)ALT mutation). c Peripheral
blood smear, Giemsa stained, from patient MC, which shows anisocytosis and poikilocytosis with some irregularly contracted cells; scale bar represents 10
μm. d Peripheral blood Hemoglobin H (HbH) preparation, brilliant cresyl blue stained, from patient MC, which shows HbH inclusions; scale bar represents
10 μm. e Southern blot analysis using a probe speciﬁc for the core of MCS-R2, which gives an 19 kb band on BglII digest genomic DNA from normal controls
and RC but not from MC conﬁrming the absence of this segment. f, g Analysis of enrichment of histone 4 (H4) acetylation f and SCL g by ChIP-qPCR in
in vitro differentiated primary erythroid cells (Fibach culture35) of MC harvested at intermediated erythroblasts stage (day 8–10 of Phase 2). The y-axis
represents enrichment relative to ChIP input, normalized to 18S control region. Mean values are presented and error bars represent SD (n= 3). Amplicons
are labeled thus: RHBDF1, intronic amplicon within the Rhomboid gene RHBDF1, used as a negative control; ALT insert, amplicon speciﬁc for 39 bp insert;
MCS-R1, the human MCS-R1 which is one of the other enhancers of α-globin; alpha-promoter, α-globin promoter; beta actin promoter, a control amplicon
over the β-actin promoter. h Analysis of the abundance of panH4 acetylation across the α-globin locus by ChIP-seq in in vitro differentiated primary
erythroid cells harvested at intermediated erythroblasts stage from patient MC (lower track) and a normal control (upper track), showing the absence of the
peak over MCS-R2 in patient MC (red dashed box)
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methylcellulose colony assays with CD34+ cells harvested
from the secondary xenograft, which again demonstrated the
presence of granulocyte/macrophage and erythroid progenitor
activity (Fig. 4f). Sanger sequencing of 40 colonies (20 erythroid
and 20 myeloid) conﬁrmed deletion of MCS-R2. These
data conﬁrm that we have successfully edited LT-HSC, which
are able to reconstitute myeloid, lymphoid, and erythroid
hematopoiesis.
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ΔMCS-R2 restores globin balance in β-thalassemia cells.
Finally, to examine the ability of the edited deletion of MCS-R2 to
rectify globin chain imbalance in the erythroid cells of patients
with β-thalassemia, we performed single colony analysis
on CRISPR-edited CD34+ cells obtained from patients with
HbE β-thalassemia (Supplementary Table 5). Genome editing of
CD34+ cells obtained from patients with HbE β-thalassemia
produced a mixture of different genotypes similar to those
observed in normal controls with comparable mutation
frequencies (Supplementary Fig. 9; Fig. 5a). As expected, the α/β
globin mRNA ratios in unmodiﬁed erythroid cells from patients
with HbE β-thalassemia were higher than α/β globin mRNA
ratios in unmodiﬁed, normal erythroid cells. However when
a heterozygous ΔMCS-R2 mutation was edited into the HbE
β-thalassemia cells, the α/β globin mRNA ratio decreased and
many individual clones had α/β globin mRNA ratios similar to
normal control clones (Fig. 5b). When both alleles at MCS-R2
were edited in cells derived from patients with HbE β-thalasse-
mia, the α/β globin ratios were rebalanced and many individual
clones had α/β globin mRNA ratios similar to those found
in normal control cells (Fig. 5b). Analysis of α/all β-like globins
(α/(α + γ)) ratios demonstrated similar trends (Fig. 5c). The-
se observations conﬁrm that editing of MCS-R2 can efﬁciently
restore globin chain balance in erythroid cells in patients with
β-thalassemia and we predict that this would result in phenotypic
improvements and improved survival of genome-edited cells
with reduced levels of erythroid cell destruction and anemia
in vivo.
Discussion
The clinical management of β-thalassemia still largely depends on
supportive treatment with RBC transfusions and iron chelation in
the majority of patients1. Allogenic bone marrow transplantation
remains the only curative treatment; however its usefulness is
limited to a minority of patients who have HLA-matched sibling
donors19. Several new therapies for β-thalassemia are currently
being investigated20. Except for a few studies21 all of these new
and experimental therapies aim to resolve globin chain imbalance
by increasing the production of γ-globin and fetal hemoglobin by
genome editing of transcription factors22, 23 (eg: BCL11A24 and
LRF/ZBTB7A25) or by pharmacological methods (eg: histone
deacetylase inhibitors26 and lysine-speciﬁc demethylase 127).
Alternatively, here we present a novel approach by directly
reducing expression of α-globin. Considering the central role of
excess α-globin chains in the pathophysiology of β-thalassemia,
and the extensive clinical evidence showing how co-inheritance
of α-thalassemia ameliorates β-thalassemia, this presents an
extremely promising approach to curing this disease until
efﬁcient gene correction of the defective β-globin by HDR in stem
cells becomes routinely possible. This approach can be used on its
own or to complement other on-going efforts of increasing the
production of fetal hemoglobin.
We have previously summarized the ﬁndings from
several clinical studies showing that a reduction of α-globin
expression to 75–25% of normal is an effective, safe, and tolerable
level to provide sustainable beneﬁcial effects in patients with
β-thalassemia3. In genome-edited normal control cells many
of the clones with heterozygous or homozygous deletions of
MCS-R2 demonstrated reduction of the α/β ratio to this desirable
range. In cells with HbE β-thalassemia mutations, targeted
deletion of MCS-R2 in both heterozygous and homozygous states
resulted in amelioration of the disturbed globin ratios.
In this paper we have demonstrated the use of CRISPR/
Cas9 system for genome editing of MCS-R2, the major α-globin
enhancer, in human primary LT-HSCs. CD34+ cells, including
LT-HSCs, are readily obtainable at a clinical scale and are
currently used in all stem cell transplantation protocols for blood
diseases. Thus the hematopoietic system offers the ideal model for
translation of genome editing for clinical beneﬁt, and successful
genome editing of lymphoid cells using a zinc-ﬁnger nuclease-
based technique has already progressed to clinical trials28.
Translation of our strategy into clinical application would require
a harvest of CD34+ cells from patients with β-thalassemia, ex vivo
genome editing, and an autograft. This would therefore avoid the
potentially life-threatening complications of graft rejection and
graft versus host disease associated with allografting for patients
with hemoglobinopathies.
Using our protocol, we currently achieve transfection efﬁciency
as high as 75% and in transfected cells the editing efﬁciency
was 70–80%, providing an overall editing rate of 50–60% of
live CD34+ cells. Previously, it has been shown that chimerism
levels of only 10–20% of normal HSCs are sufﬁcient to result
in nearly complete hematologic and pathologic correction of
β-thalassemia29, 30. Therefore, using our strategy, we should be able
to provide sufﬁcient numbers of genome-edited HSCs to produce a
clinically signiﬁcant beneﬁcial effect in patients with β-thalassemia.
One potential limitation of this strategy is that deletion of
MCS-R2 could lead to profound reduction in α-globin expression
thus causing a critical decrease in total globin synthesis in some
edited cells. However, it is likely that erythroid cells with more
balanced globin chain synthesis generated from genome-edited
HSCs will have less ineffective erythropoiesis and hemolysis and
remain in the circulation for the full life-span thus demonstrating
selective advantage for survival in vivo. Furthermore, genome
engineering of the MCS-R2 enhancer could be used to ﬁne-tune
the level of α-globin expression by limiting the edit to already
identiﬁed transcription factor binding sites within the enhancer.
Therefore, the issue of excessive downregulation of α-globin need
not be a signiﬁcant barrier during future clinical use.
Xenograft assays performed here show that CRISPR/Cas9
genome editing is not limited to progenitor cells but also occurs
in LT-HSCs. These are the cells, which must be edited if a sus-
tainable improvement is to be achieved in patients with
β-thalassemia. We have shown that edited HSCs give rise to
multiple lineages of hematopoietic cells in vivo. In the xenograft
Fig. 2 Deletion of MCS-R2 using CRISPR/Cas9 genome editing in human CD34+ cells. a Schematic of sgRNA target sites. Four sgRNAs (Cr1, Cr2, Cr9, and
Cr10) were designed to target the 5′ end of the MCS-R2 core element, whereas three sgRNAs (Cr7, Cr8, and Cr12) target the 3′ end. b Representative ﬂow
cytometry plots showing GFP expression and forward scatter (FS) after gating for live cells in non-transfection control (NTC), Cas9 control (C9), and
CRISPR/Cas9 plasmid pair-transfected cells. Orange: GFP negative, blue: GFP positive (low), and green: GFP positive (high). Mean and SD of the percentage
of cells within each region is indicated (n= 3). Gating strategy is shown in Supplementary Fig. 10a. c Representative gel electrophoresis image of genomic
DNA extracted from cells targeted by four CRISPR/Cas9 plasmid pairs analyzed by PCR. d Gene editing deletion induction efﬁciency as measured
independently by percentages of mutated alleles determined by band size in end-point PCR and subsequent Sanger sequence analysis and by determining
inverse of proportions of amplicons inside: outside deletion (amplicons of same length) by multiplexed droplet digital PCR; mean values are presented and
error bars represent SD (n= 3). e Characterization of deletion break points by sequencing (co-ordinates from Hum Mar 2006 (NCBI36/hg18) assembly).
f α-and β-globin gene expression normalized to the expression of RPL13A and α/β-globin mRNA ratios relative to Cas9 control (C9) analyzed by qPCR; error
bars represent SD (n= 3); *P< 0.05 and **P< 0.01 relative to C9 (Student’s t-test). C9 Cas9-only control
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assays we observed a single, slightly larger deletion in mice that
had genome-edited cells. This suggests highly oligo or mono-
clonal reconstitution that may have resulted from a limited
number or even a single LT-HSC. This is not entirely surprising
as LT-HSCs are rare within the CD34+ population of cells and
this does not detract from the conclusion that the editing
procedure does result in the engineering of this population of
cells. A xenografted mouse is not a suitable model in which to
study erythropoiesis from transplanted cells and therefore we
were not able to analyze the effect of ΔMCS-R2 on globin
gene expression in vivo. However, there is no reason to think
that expression in vivo will be any different from that seen in
erythroid cells differentiated from CD34+ cells in culture.
An important consideration is whether editing a major
enhancer would have effects on any other features of
erythropoiesis or in other tissues. We addressed this by detailed
analysis of a family with a rare natural deletion of MCS-R2. The
two affected individuals with heterozygous and homozygous
mutations of MCS-R2 are healthy with no other obvious
phenotypes except for anemia validating MCS-R2 as a safe region
of the genome to be targeted by genome editing. Furthermore,
detailed evaluation of predicted off-target effects of genome
editing tools used in our study did not reveal any off-target
activity and the effects were speciﬁc to the target loci.
In conclusion, we have shown that it is feasible to edit
LT-HSCs and to inactivate an enhancer, which speciﬁcally and
uniquely regulates α-globin expression. Importantly, this reduces
α-globin expression to the levels known to be required to achieve
beneﬁcial effects in patients with β-thalassemia. These ﬁndings
open up a new approach to ameliorate this life-limiting disease
and provide useful insights into plausible therapeutic approaches
to human genetic diseases in general.
Methods
Cell culture. Human umbilical cord blood and adult peripheral blood buffy coat
residues were purchased from the National Health Service (NHS) Blood and
Transplant, UK. Samples from β-thalassemia patients were collected after obtaining
informed written consent. Ethical approval for the study was granted by North
West Research Ethics Committee of NHS National Research Ethics Services
(reference no. 03/08/097). Mononuclear cells were separated using Histopaque-
1077 Hybri-Max (Sigma), the CD34+ cells were puriﬁed using a CD34 MicroBead
Kit (Miltenyl Biotech Cat. 130-046-702) and purity conﬁrmed by FACS. Primary
CD34+ cells were not tested for mycoplasma contamination. Then the CD34+ cells
were differentiated into erythroid cells over 21 days using a two-phase liquid
culture system which used StemSpan SFEM II (Stemcell Technologies). Phase 1
medium was supplemented with stem cell factor, interleukin-3, human
recombinant erythropoietin (EPO) (0.5 U/ml) and cholesterol-rich lipids. Phase 2
medium was similar to phase 1 medium except for addition of iron saturated
holotransferrin and higher concentration of EPO (3 U/ml). In single-cell
experiments, single cells were sorted into the wells in Terasaki multiwell plates
and were cultured in 20 μl culture medium.
CRISPR plasmids. Several sgRNA-targeting MCS-R2 were cloned into the
Addgene plasmid 48138 (pSpCas9(BB)-2A-GFP (pX458)) backbone vector. Guides
were cloned into the BbsI restriction site containing two Guanine residues at
positions 0 and 1 of the protospacer, the sequence of the targeting guides are listed
in Supplementary Table 2.
Transfection of CD34+ cells. Transfection of CRISPR plasmid DNA into
CD34+ cells was done using Amaxa human CD34+ cell nucleofector kit
(Lonza) and Amaxa nucleofector I device (Lonza)31. Culture medium containing
3 × 105–1 × 106 cells was spun at 1200 rpm for 5 min. The cell pellet was
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Fig. 5 Deletion of MCS-R2 in CD34+ cells from HbE β-thalassemia patients using Cr2 + Cr12. a Frequency of different types of mutations generated.
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resuspended in 100 µl nucleofection solution and was nucleofected with 10 μg
CRISPR plasmid DNA in the cuvette provided using the U-08 program. Cell
suspension was incubated at room temperature for 10 min in nucleofection
solution before transferring it to antibiotic-free medium.
Flow cytometry. Antibody labeling of washed cells was done using the following
anti-human antibodies; allophycocyanin (APC)-conjugated anti-CD34,
ﬂuorescein isothiocyanate (FITC)-conjugated anti-CD71, phycoerythrin (PE)
conjugated anti-CD235a, APC-conjugated anti-CD45, FITC-conjugated anti-
CD19, and PE-conjugated anti-CD33. Dead cells were identiﬁed by Hoechst 33258
pentahydrate nucleic acid stain (Invitrogen) and were excluded. Analysis was
performed on Cyan ADP (Beckman Coulter) analyzer using Summit v4.3 and
FlowJo V10 softwares and cell sorting was performed in a BD FACSAria Fusion cell
sorter (BD Biosciences). Details of ﬂow cytometry gating strategy are given in
Supplementary Fig. 10.
Antibodies used for ﬂow cytometry. Antibodies to the following proteins were
used: APC-conjugated anti-CD34 (Miltenyl Biotec Cat. 130-090-654; dilution
1:100), FITC-conjugated anti-CD71 (BD Biosciences Cat. 555536; dilution 1:100),
PE-conjugated anti-CD235a (BD Biosciences Cat. 340947; dilution 1:500),
APC-conjugated anti-CD45 (BioLegend Cat. 304012 Clone HI30; dilution 1:100),
FITC-conjugated anti-CD19 (BioLegend Cat. 302206 Clone HIB19; dilution 1:100),
and PE-conjugated anti-CD33 (BioLegend Cat. 303404 Clone WM53; dilution
1:100). Dead cells were identiﬁed by Hoechst 33258 pentahydrate nucleic acid stain
(Invitrogen; dilution 1:10,000) and were excluded.
DNA extraction and PCR. Genomic DNA from cell pellets was extracted using
DNeasy blood and tissue kit (Qiagen) and genomic DNA from small cell numbers
was ampliﬁed directly from cell lysate using Illustra single-cell GenomiPhi DNA
ampliﬁcation kit (GE Healthcare). PCR reactions across MCS-R2 region were
performed with AmpliTaq Gold 360 PCR master mix (Invitrogen) using a custom
designed primer pair (forward 5′-TGGTCCTGAAGGATGAGAAG-3′; reverse
5′-AGCAACAGTCCTTTCTCTGG-3′). Uncropped scans of all PCR gels are
shown in the Supplementary Fig. 11.
Droplet digital PCR. About 20 ng genomic DNA was ampliﬁed with a primer
pair, one set with a primer within the deletion (5′-GGCCCAGTTATCTGCTC
CCTCAAGT-3′) and a primer upstream (5′-AGGCCCATATCTCTGCCCAA-
GAGC-3′) and the other set both 3.9 kb downstream (forward 5′-GGGGACTT
TTGCCATGCCTGAAGTAGA-3′; reverse 5′-GGCCCCACTCCCTGATCT-
TAACCATTT-3′), using the QX200 Droplet Digital PCR System. Around 20,000
droplets were evaluated and the gene editing efﬁciency of the different CRISPR
sgRNA pairs was estimated by comparing the two primer sets against a negative
control (vector only).
Identiﬁcation of potential off-target loci for CRISPR plasmids. Potential
genic off-target loci were identiﬁed using the Sanger off-target prediction tool
(http://www.sanger.ac.uk/htgt/wge/ﬁnd_off_targets_by_seq_allowing_up_
to_four_mismatches) (Supplementary Table 3). These loci were captured by
hybridization to complementary 50 bp biotinylated oligos prior to sequencing;
these oligonucleotides (IDT) were designed to bind within 50 bp of either side of
the CRISPR/Cas9 target and off-target sites using an in-house PERL script (Off-
TargetProbes.pl). For each site, one oligo from each adjacent window was selected;
selected oligos had the lowest BLAT density score and were only used if the score
was below 35 and no simple repeats were present32. Chromosome capture oligos
were successfully designed for 53/57 potential off-target sites: 22 potential off-target
sites for Cr1, 6 potential off-target sites for Cr8, 8 potential off-target sites for Cr2,
and 17 potential off-target sites for Cr12. (details in the Supplementary Table 3).
Most sites had two capture oligos, but for some it was possible to design only one.
Analysis of off-target loci. Whole-genome ampliﬁed DNA was prepared (Illustra
single-cell GenomiPhi DNA ampliﬁcation kit, GE Healthcare) from 30 clones and
combined in pools of ﬁve clones, each contributing equal amounts of DNA, and
sonicated to 200 bp (Covaris S220 sonicator). Sonicated DNA was puriﬁed with
Agencourt AMPure XP beads (Beckman Coulter) and indexed using NebNext
Ultra II (New England Biolabs). Fragment size was conﬁrmed before and after
indexing using the D1000 Tapestation (Agilent).
The capture was performed using four pools of ﬁve clones for Cr2 and Cr12,
and for two pools of ﬁve clones for Cr1 and Cr8. Up to 2 µg of each library pool
was combined for multiplexed capture with capture-based enrichment of target
and off-target regions. This was carried out in two successive rounds of
hybridization, biotin pull down, and ampliﬁcation with SeqCap EZ (Nimblegen)
and M-280 Streptavadin Dynabeads (ThermoFisher) following the NG Capture-C
method33. Each of these pools was sequenced as a separate library with the
captured fragments sequenced in a 150 bp paired end (300 cycles mid output) run
on the MiSeq Platform (Illumina).
The reads were mapped to the hg38 genome build, using bowtie2,
(default parameters, —maxins 700), allowing only paired concordant mapping
to be reported. The un-mapping read pairs were trimmed with trim_galore
(default parameters), and re-mapped in bowtie2. This resulted in 91–93% mapping.
STAR mapping was used to map the remaining reads (ﬁrst end-to-end mapping,
then setting insertion elongation penalty to zero, and ﬁnally also allowing single
end mapping). Each of these rounds mapped ~90% of the previously unmapped
reads, resulting in overall mapping of 99.9%. No new sequencing artifacts were
introduced by this process. The mapped data were compared to the reference
sequence, by using samtools mpileup, and further excluding all bases in reads
with lower quality score than 30, by using varscan. This resulted in read depth for
each base of 40,000–200,000 (except sample 4 for Cr2 and 12, which had 13,000).
The counts were normalized to 10,000 counts.
RNA extraction and qRT-PCR. Total RNA was puriﬁed using RNeasy mini kit
(Qiagen) and cDNA from small number of cells was directly prepared from cell lysate
using TaqMan gene expression cells-to-CT kit (Life Technologies). All qRT-PCR
reactions were performed using inventoried TaqMan assays (Applied Biosystems;
TaqMan IDs: HBA2/HBA1-Hs00361191_g1, HBB-Hs00747223_g1, HBG-
Hs00361131_g1 and RPL13A-Hs03043885_g1) in technical triplicate in 7500 fast real-
time PCR system (Applied Biosystems) according to the manufacturer’s protocol.
Data were analyzed by 7500 software v2.0.6 using the delta delta CT method.
ChIP and ChIP-seq. Chromatin immunopreciptation was performed as previously
described34. Brieﬂy, 1 × 107 cells from primary erythroid cultures were ﬁxed with
1% formaldehyde, before neutralization, and lysis in SDS ChIP lysis buffer
(Millipore ChIP kit, 17-295). Pre-clearing was performed with protein agarose A
beads before overnight incubation with antibody, and subsequent agarose bead
precipitation. Washes were performed according to the manufacturer’s protocol.
Antibodies used were anti-pan-H4 acetylation and anti-SCL. ChIP-seq libraries
were prepared and sequenced using the standard Illumina paired-end protocol.
Antibodies used for ChIP. Antibodies to the following proteins were used:
anti-pan-H4 acetylation (Upstate 17-630; dilution 1:200) and anti-SCL (kindly
supplied by Professor Catherine Porcher, MRC Molecular Haematology Unit,
Weatherall Institute of Molecular Medicine, Oxford; dilution 1:200).
Southern blotting. Southern blotting was performed using standard methods. A 538
bp probe binding the region over MCS-R2 (chr16: 163380—163907 on build hg19)
was generated by PCR, using primers FWD 5′-AACAAGAAAACCAGCAG
GCTCC-3′ and REV 5′-TGTAAGTCCATCCAGGTGTGAGTTC-3′. This was
cloned into the vector pGEM-T-easy (Promega) for conﬁrmation by sequencing prior
to excision and puriﬁcation. About 50 ng of probe was end-labeled with α-P32 using
the megaprime kit (Amersham, RPN1604) and hybridized to blotted genomic DNA
from patient MC, RC, and a normal control, digested using BamH1. A labeled
fragment size of 19 kb is expected when hybridized with the MCS-R2 probe.
Sequence analysis. PCR sequencing was performed on PCR products puriﬁed with
Qiaquick Gel Extraction Kit (Manufacturer Qiagen Cat No 28704) or Qiaquick PCR
Puriﬁcation Kit (Manufacturer Qiagen Cat No 28104) and then sequenced with
the ampliﬁcation primers using BigDye Terminator v3.1 Cycle Sequencing Kit
(Manufacturer ThermoFisher Scientiﬁc Cat No 4337455) as per the manufacturer’s
instructions. The products were then cleaned with a standard ethanol precipitation
and run on an AB3730 DNA Analyzer (ThermoFisher Scientiﬁc) and analyzed
using DNA analysis software Sequencer 5.0.1 (Gene Codes Corporation).
Colony forming unit assay. Single-cell suspensions were mixed into Methocult
Optimum (Manufacturer Stemcell Technologies Cat No H4034) to allow
progenitor cells to expand and differentiate into myeloid or erythroid colonies
as per the manufacturer’s instructions. Colonies were inspected and picked
manually into PBS using a light inverted microscope, EVOS XL Imaging System
(Manufacturer ThermoFisher Scientiﬁc Cat No AME3300).
Animal models and xenotransplantation assay. Female NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ, Jackson Laboratory, USA) mice (species-Mus musculus) were used
for xenotransplantation assays. Ten- to 14-week-old NSG mice were irradiated twice
with 100 cGy, 4 h apart. Cells were administered via intra-tibial injection within 24 h
of the second irradiation. Four mice were injected during the ﬁrst transplantation
experiment and three mice received injections during the secondary transplantation
experiment. Human CD45(hCD45)+33 + 19− (myeloid) or hCD45+33-19+
(B-lymphoid) engraftment was analyzed by FACS and deﬁned as ≥0.1% of live
mononuclear cell gate. Mice were killed for cell harvesting from lower limb, pelvic,
and vertebral bones at 12 weeks post injection. Permission was granted to perform
animal experiments by the UK Government Home Ofﬁce through the Project
License 30/2465
Statistical analysis. Exact sample sizes and representations of error bars are
indicated in each ﬁgure. All experiments were performed in triplicate unless
speciﬁed otherwise. A two-tailed unpaired Student’s t-test was used in statistical
analysis between groups for normally distributed data and Mann–Whitney U-test
was used for data, which are not normally distributed; comparison groups are
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mentioned in each ﬁgure. Differences corresponding to P< 0.05 were considered
statistically signiﬁcant. No statistical method was used to predetermine sample size
and data analysis was not blinded. No samples, mice, or data points were excluded
from the reported analysis. No randomization method was used in experiments.
Data availability. All sequencing data sets are available at the National Center for
Biotechnology Information Gene Expression Omnibus (NCBI GEO) with accession
numbers GSE95370, GSM2508191, GSM2508192, GSM2508193, GSM2508194,
GSM2508195, GSM2508196.
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